Real-world safety and efficacy of Anti-VEGF treatment in Brazil.

IF 1.1 4区 医学 Q3 OPHTHALMOLOGY
Arquivos brasileiros de oftalmologia Pub Date : 2025-04-28 eCollection Date: 2025-01-01 DOI:10.5935/0004-2749.2024-0277
Mario Cesar Bulla, Daniel Lavinsky
{"title":"Real-world safety and efficacy of Anti-VEGF treatment in Brazil.","authors":"Mario Cesar Bulla, Daniel Lavinsky","doi":"10.5935/0004-2749.2024-0277","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This retrospective study evaluated the safety and efficacy of real-world antiangiogenic therapy for ocular conditions in the private healthcare sector in southern Brazil.</p><p><strong>Methods: </strong>Medical records from patients who underwent intravitreal anti-vascular endothelial growth factor injections over the past 12 years were reviewed retrospectively. Data collection included the primary diagnoses, drugs administered, injection techniques, adverse effects, and treatment efficacy. Efficacy was assessed by comparing preand posttreatment visual acuity and central subfield thickness in eyes with followup exceeding 2 years.</p><p><strong>Results: </strong>A total of 1,024 patients, 1,310 treated eyes, and 11,377 injections were analyzed. The injections included aflibercept (6,833), ranibizumab (3,692), bevacizumab (843), and brolucizumab (9), administered either bilaterally (3,696) or unilaterally (7,681). The most common diagnoses were diabetic macular edema, exudative age-related macular degeneration, retinal vein occlusion related macular edema, and proliferative diabetic retinopathy. No endophthalmitis cases were reported. Vitritis with transient visual acuity loss occurred in two cases following aflibercept injections. One retinal detachment case was successfully treated with vitrectomy. The median number of injections per patient was 6 (IQR [interquartile range], 3-13). Among 445 eyes from 328 patients with followup over 2 years (median, 4.05 years; IQR, 2.89-6.29), there was a significant improvement in best-corrected visual acuity from 0.3 to 0.4 (Snellen) (p<0.001) and a reduction in central subfield thickness from 361 to 267 microns (p<0.001). CST comparisons included patients with age-related macular degeneration, diabetic macular edema, and retinal vein occlusion related macular edema.</p><p><strong>Conclusion: </strong>This real-world study, the largest of its kind in Brazil, confirms the safety and efficacy of antiangiogenic therapies in the southern Brazilian private healthcare system. The findings highlight a low incidence of severe adverse events and outcomes consistent with global studies, supporting the ongoing use of antiangiogenic agents as effective and well-tolerated treatments for various ocular conditions in developing countries.</p>","PeriodicalId":8397,"journal":{"name":"Arquivos brasileiros de oftalmologia","volume":"88 4","pages":"e20240277"},"PeriodicalIF":1.1000,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arquivos brasileiros de oftalmologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5935/0004-2749.2024-0277","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: This retrospective study evaluated the safety and efficacy of real-world antiangiogenic therapy for ocular conditions in the private healthcare sector in southern Brazil.

Methods: Medical records from patients who underwent intravitreal anti-vascular endothelial growth factor injections over the past 12 years were reviewed retrospectively. Data collection included the primary diagnoses, drugs administered, injection techniques, adverse effects, and treatment efficacy. Efficacy was assessed by comparing preand posttreatment visual acuity and central subfield thickness in eyes with followup exceeding 2 years.

Results: A total of 1,024 patients, 1,310 treated eyes, and 11,377 injections were analyzed. The injections included aflibercept (6,833), ranibizumab (3,692), bevacizumab (843), and brolucizumab (9), administered either bilaterally (3,696) or unilaterally (7,681). The most common diagnoses were diabetic macular edema, exudative age-related macular degeneration, retinal vein occlusion related macular edema, and proliferative diabetic retinopathy. No endophthalmitis cases were reported. Vitritis with transient visual acuity loss occurred in two cases following aflibercept injections. One retinal detachment case was successfully treated with vitrectomy. The median number of injections per patient was 6 (IQR [interquartile range], 3-13). Among 445 eyes from 328 patients with followup over 2 years (median, 4.05 years; IQR, 2.89-6.29), there was a significant improvement in best-corrected visual acuity from 0.3 to 0.4 (Snellen) (p<0.001) and a reduction in central subfield thickness from 361 to 267 microns (p<0.001). CST comparisons included patients with age-related macular degeneration, diabetic macular edema, and retinal vein occlusion related macular edema.

Conclusion: This real-world study, the largest of its kind in Brazil, confirms the safety and efficacy of antiangiogenic therapies in the southern Brazilian private healthcare system. The findings highlight a low incidence of severe adverse events and outcomes consistent with global studies, supporting the ongoing use of antiangiogenic agents as effective and well-tolerated treatments for various ocular conditions in developing countries.

巴西抗vegf治疗的真实世界安全性和有效性。
目的:本回顾性研究评估了巴西南部私营医疗部门眼疾抗血管生成治疗的安全性和有效性。方法:回顾性分析过去12年玻璃体内注射抗血管内皮生长因子患者的病历。资料收集包括初步诊断、给药、注射技术、不良反应和治疗效果。随访超过2年,通过比较治疗前后的视力和眼中心亚野厚度来评价疗效。结果:共分析1024例患者,1310只治疗眼,11377次注射。注射药物包括阿非利西普(6833)、雷尼单抗(3692)、贝伐单抗(843)和博鲁单抗(9),双侧注射(3696)或单侧注射(7681)。最常见的诊断是糖尿病性黄斑水肿、渗出性老年性黄斑变性、视网膜静脉阻塞相关性黄斑水肿和增殖性糖尿病视网膜病变。无眼内炎病例报告。2例注射阿布西贝后发生玻璃体炎伴短暂性视力丧失。玻璃体切除术成功治疗1例视网膜脱离。每位患者注射次数中位数为6次(IQR[四分位间距],3-13)。328例患者的445只眼随访超过2年(中位数4.05年;IQR, 2.89-6.29),最佳矫正视力从0.3显著提高到0.4 (Snellen) (p结论:这项巴西同类研究中规模最大的真实世界研究,证实了巴西南部私人医疗保健系统中抗血管生成疗法的安全性和有效性。研究结果强调了严重不良事件的低发生率和与全球研究一致的结果,支持在发展中国家持续使用抗血管生成药物作为有效和耐受性良好的各种眼部疾病治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.60
自引率
0.00%
发文量
200
审稿时长
6-12 weeks
期刊介绍: The ABO-ARQUIVOS BRASILEIROS DE OFTALMOLOGIA (ABO, ISSN 0004-2749 - print and ISSN 1678-2925 - (ABO, ISSN 0004-2749 - print and ISSN 1678-2925 - electronic version), the official bimonthly publication of the Brazilian Council of Ophthalmology (CBO), aims to disseminate scientific studies in Ophthalmology, Visual Science and Health public, by promoting research, improvement and updating of professionals related to the field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信